Outlook Therapeutics (OTLK) Net Cash Flow Growth (3y) (2018 - 2026)
Outlook Therapeutics (OTLK) Net Cash Flow Growth (3y) (2018 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
- |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
89.97% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-13.44% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
33.37% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Outlook Therapeutics |
51.13 Mn |
43.39 Mn |
-21,888.00 |
52.58% |
| Date | Value |
|---|
| Mar 31, 2026 |
52.58% |
| Dec 31, 2025 |
-74.28% |
| Sep 30, 2025 |
54.40% |
| Jun 30, 2025 |
26.86% |
| Mar 31, 2025 |
29.23% |
| Dec 31, 2024 |
-29.38% |
| Sep 30, 2024 |
-48.56% |
| Jun 30, 2024 |
4.54% |
| Mar 31, 2024 |
5.28% |
| Dec 31, 2023 |
-23.22% |
| Sep 30, 2023 |
3.32% |
| Jun 30, 2023 |
-35.56% |
| Mar 31, 2023 |
-66.61% |
| Dec 31, 2022 |
93.36% |
| Sep 30, 2022 |
-12.79% |
| Jun 30, 2022 |
-63.07% |
| Mar 31, 2022 |
-445.49% |
| Dec 31, 2021 |
240.20% |
| Sep 30, 2021 |
19.72% |
| Jun 30, 2021 |
-70.79% |
